{"id":"prilosec-otc","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":{"setId":"35a79458-79f6-44d6-b74c-b4f4aaf0dde0","title":"PRILOSEC OTC (OMEPRAZOLE MAGNESIUM) TABLET, DELAYED RELEASE [THE PROCTER & GAMBLE MANUFACTURING COMPANY]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Omeprazole, the active ingredient, irreversibly binds to and inhibits the H+/K+-ATPase enzyme (proton pump) on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid secretion, significantly reducing intragastric acidity. The effect is sustained and dose-dependent, providing relief from acid-related symptoms over several days of treatment.","oneSentence":"Prilosec OTC inhibits the proton pump in gastric parietal cells, reducing stomach acid production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:39.809Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Frequent heartburn (≥2 days per week)"},{"name":"Over-the-counter acid reflux symptom relief"}]},"trialDetails":[{"nctId":"NCT07007806","phase":"PHASE1","title":"Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-05-09","conditions":"Healthy Volunteer Study","enrollment":20},{"nctId":"NCT01275170","phase":"PHASE1","title":"A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-28","conditions":"Infectious Disease","enrollment":49},{"nctId":"NCT00446004","phase":"PHASE1","title":"Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2007-04","conditions":"Healthy","enrollment":15},{"nctId":"NCT00808769","phase":"PHASE4","title":"Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression","status":"COMPLETED","sponsor":"Procter and Gamble","startDate":"2008-11","conditions":"Normal Healthy Subject Population","enrollment":30},{"nctId":"NCT00765206","phase":"PHASE3","title":"A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-05","conditions":"Gastric Acid, Human Experimentation","enrollment":60},{"nctId":"NCT00674115","phase":"PHASE3","title":"A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Gastric Acid, Human Experimentation","enrollment":60},{"nctId":"NCT01337804","phase":"PHASE1","title":"A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01","conditions":"Heartburn","enrollment":50},{"nctId":"NCT01557335","phase":"PHASE1","title":"A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540","status":"COMPLETED","sponsor":"POZEN","startDate":"2010-11","conditions":"Platelet Aggregation","enrollment":30},{"nctId":"NCT00903448","phase":"PHASE4","title":"Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression","status":"COMPLETED","sponsor":"Procter and Gamble","startDate":"2009-04","conditions":"Healthy","enrollment":40},{"nctId":"NCT01170169","phase":"PHASE1","title":"Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2006-01","conditions":"Healthy","enrollment":44},{"nctId":"NCT01170182","phase":"PHASE1","title":"Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2006-02","conditions":"Healthy","enrollment":54},{"nctId":"NCT01045434","phase":"PHASE1","title":"Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2006-12","conditions":"Healthy","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Prilosec OTC®","genericName":"Prilosec OTC®","companyName":"Procter and Gamble","companyId":"procter-and-gamble","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prilosec OTC inhibits the proton pump in gastric parietal cells, reducing stomach acid production. Used for Frequent heartburn (≥2 days per week), Over-the-counter acid reflux symptom relief.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}